Corvus Pharmaceuticals, Inc. 8-K

What Happened
Corvus Pharmaceuticals, Inc. announced on January 21–22, 2026 that it entered into an underwriting agreement with Jefferies LLC and Goldman Sachs & Co. LLC for an underwritten public offering of common stock. The offering consists of 7,900,677 shares at a public offering price of $22.15 per share, and the underwriters exercised a 30‑day option on January 22, 2026 to purchase an additional 1,185,101 shares. The offering was expected to close on January 23, 2026, subject to customary closing conditions.

Key Details

• Shares offered: 7,900,677 common shares at $22.15 per share.
• Option exercised: 1,185,101 additional shares exercised in full on Jan 22, 2026.
• Underwriter purchase price: $20.821 per share (before underwriting discounts/commissions).
• Net proceeds: approximately $163.6 million (base offering) and approximately $188.3 million after giving effect to the underwriters’ full exercise of the option.
• Intended use of proceeds: working capital and general corporate purposes, which may include capital expenditures, research & development (including Phase 3 T‑cell lymphoma and Phase 2 trials in atopic dermatitis, hidradenitis suppurativa and asthma), sales & marketing, and administrative expenses.
• Closing conditions and customary representations, indemnities and termination provisions apply.

Why It Matters
This financing will materially increase Corvus’s cash resources (roughly $188M if option fully exercised), providing funding for ongoing clinical programs and corporate operations. For investors, the offering dilutes existing shareholders but supports the company’s development plans for key clinical trials; the filing also notes the offering is subject to customary closing conditions and contains forward‑looking statements.